Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1959 1
1961 2
1962 1
1963 2
1964 7
1965 5
1966 2
1968 3
1969 1
1970 4
1971 2
1972 2
1973 1
1974 1
1975 9
1976 7
1977 5
1978 10
1979 11
1980 9
1981 8
1982 16
1983 16
1984 19
1985 19
1986 21
1987 19
1988 12
1989 16
1990 14
1991 18
1992 23
1993 18
1994 12
1995 28
1996 25
1997 29
1998 44
1999 31
2000 41
2001 47
2002 40
2003 50
2004 47
2005 50
2006 60
2007 55
2008 82
2009 80
2010 64
2011 79
2012 94
2013 91
2014 114
2015 112
2016 123
2017 135
2018 123
2019 130
2020 217
2021 203
2022 99
2023 103
2024 208
2025 292
2026 58

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,958 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.
Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, Hou P, Cui Q, Xu Z, Wang W, Yu Z, Zhao L, He M, Wang Y, Fu C, Wei M, Yu L. Wang R, et al. J Hematol Oncol. 2025 Apr 30;18(1):51. doi: 10.1186/s13045-025-01704-3. J Hematol Oncol. 2025. PMID: 40307936 Free PMC article. Review.
Additionally, ADCs are being investigated as potential therapeutic candidates for autoimmune diseases, persistent bacterial infections, and other challenging indications. Despite their therapeutic benefits, the development and application of ADCs face significant challenge …
Additionally, ADCs are being investigated as potential therapeutic candidates for autoimmune diseases, persistent bacterial infection …
A pan-cancer analysis of the microbiome in metastatic cancer.
Battaglia TW, Mimpen IL, Traets JJH, van Hoeck A, Zeverijn LJ, Geurts BS, de Wit GF, Noë M, Hofland I, Vos JL, Cornelissen S, Alkemade M, Broeks A, Zuur CL, Cuppen E, Wessels L, van de Haar J, Voest E. Battaglia TW, et al. Cell. 2024 Apr 25;187(9):2324-2335.e19. doi: 10.1016/j.cell.2024.03.021. Epub 2024 Apr 9. Cell. 2024. PMID: 38599211 Free article.
We identified organ-specific tropisms of microbes, enrichments of anaerobic bacteria in hypoxic tumors, associations between microbial diversity and tumor-infiltrating neutrophils, and the association of Fusobacterium with resistance to immune checkpoint blockade (ICB) in …
We identified organ-specific tropisms of microbes, enrichments of anaerobic bacteria in hypoxic tumors, associations between microbia …
Microbiota-driven antitumour immunity mediated by dendritic cell migration.
Lin NY, Fukuoka S, Koyama S, Motooka D, Tourlousse DM, Shigeno Y, Matsumoto Y, Yamano H, Murotomi K, Tamaki H, Irie T, Sugiyama E, Kumagai S, Itahashi K, Tanegashima T, Fujimaki K, Ito S, Shindo M, Tsuji T, Wake H, Watanabe K, Maeda Y, Enokida T, Tahara M, Yamashita R, Fujisawa T, Nomura M, Kawazoe A, Goto K, Doi T, Shitara K, Mano H, Sekiguchi Y, Nakamura S, Benno Y, Nishikawa H. Lin NY, et al. Nature. 2025 Aug;644(8078):1058-1068. doi: 10.1038/s41586-025-09249-8. Epub 2025 Jul 14. Nature. 2025. PMID: 40659786 Free PMC article.
Here, we show that a new strain of the bacterial genus Hominenteromicrobium (designated YB328) isolated from the faeces of patients who responded to programmed cell death 1 (PD-1) blockade augmented antitumour responses in mice. ...
Here, we show that a new strain of the bacterial genus Hominenteromicrobium (designated YB328) isolated from the faeces of patients w …
Post-translational modifications in drug resistance.
Miao C, Huang Y, Zhang C, Wang X, Wang B, Zhou X, Song Y, Wu P, Chen ZS, Feng Y. Miao C, et al. Drug Resist Updat. 2025 Jan;78:101173. doi: 10.1016/j.drup.2024.101173. Epub 2024 Nov 21. Drug Resist Updat. 2025. PMID: 39612546 Free article. Review.
PTMs are involved in antitumor drug resistance, not only as inducers of drug resistance but also as targets for reversing drug resistance. Bacteria exhibit multiple PTMs-mediated antimicrobial drug resistance. PTMs allow viral proteins and host cell proteins to form comple …
PTMs are involved in antitumor drug resistance, not only as inducers of drug resistance but also as targets for reversing drug resistance. …
Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses.
Zhu X, Hu M, Huang X, Li L, Lin X, Shao X, Li J, Du X, Zhang X, Sun R, Tong T, Ma Y, Ning L, Jiang Y, Zhang Y, Shao Y, Wang Z, Zhou Y, Ding J, Zhao Y, Xuan B, Zhang H, Zhang Y, Hong J, Fang JY, Xiao X, Shen B, He S, Chen H. Zhu X, et al. Cell Metab. 2025 Apr 1;37(4):806-823.e6. doi: 10.1016/j.cmet.2024.12.013. Epub 2025 Feb 4. Cell Metab. 2025. PMID: 39909032
Notably, we characterized five response-associated enterotypes, each linked to specific bacterial taxa and metabolites. Among these, the metabolite phenylacetylglutamine (PAGln) was negatively correlated with response and shown to attenuate anti-PD-1 efficacy in vivo. ...
Notably, we characterized five response-associated enterotypes, each linked to specific bacterial taxa and metabolites. Among these, …
Intratumoral Microbiota as a Target for Advanced Cancer Therapeutics.
Peng F, Hu M, Su Z, Hu L, Guo L, Yang K. Peng F, et al. Adv Mater. 2024 Sep;36(38):e2405331. doi: 10.1002/adma.202405331. Epub 2024 Jul 26. Adv Mater. 2024. PMID: 39054925 Review.
These approaches encompass oncolytic therapy utilizing tumor-associated bacteria, the design of biomaterials based on intratumoral bacteria, the use of intratumoral bacterial components for drug delivery systems, and comprehensive strategies aimed at the erad …
These approaches encompass oncolytic therapy utilizing tumor-associated bacteria, the design of biomaterials based on intratumoral …
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.
Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, Sogari A, Toh TS, Balaban NQ, Batlle E, Bernards R, Garnett MJ, Hangauer M, Leucci E, Marine JC, O'Brien CA, Oren Y, Patton EE, Robert C, Rosenberg SM, Shen S, Bardelli A. Russo M, et al. Nat Rev Cancer. 2024 Oct;24(10):694-717. doi: 10.1038/s41568-024-00737-z. Epub 2024 Sep 2. Nat Rev Cancer. 2024. PMID: 39223250 Free PMC article. Review.
Orthogonal approaches have revealed that a subset of cells, known as drug-tolerant 'persister' (DTP) cells, have a prominent role in drug resistance. Although long recognized in bacterial populations which have acquired resistance to antibiotics, the presence of DTPs in va …
Orthogonal approaches have revealed that a subset of cells, known as drug-tolerant 'persister' (DTP) cells, have a prominent role in drug re …
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Routy B, Lenehan JG, Miller WH Jr, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Punčochář M, Ernst S, Logan D, Belanger K, Esfahani K, Richard C, Ninkov M, Piccinno G, Armanini F, Pinto F, Krishnamoorthy M, Figueredo R, Thebault P, Takis P, Magrill J, Ramsay L, Derosa L, Marchesi JR, Parvathy SN, Elkrief A, Watson IR, Lapointe R, Segata N, Haeryfar SMM, Mullish BH, Silverman MS, Burton JP, Maleki Vareki S. Routy B, et al. Nat Med. 2023 Aug;29(8):2121-2132. doi: 10.1038/s41591-023-02453-x. Epub 2023 Jul 6. Nat Med. 2023. PMID: 37414899 Clinical Trial.
Responders experienced an enrichment of immunogenic and a loss of deleterious bacteria following FMT. Avatar mouse models confirmed the role of healthy donor feces in increasing anti-PD-1 efficacy. ...
Responders experienced an enrichment of immunogenic and a loss of deleterious bacteria following FMT. Avatar mouse models confirmed t …
Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites.
Teng Y, Luo C, Qiu X, Mu J, Sriwastva MK, Xu Q, Liu M, Hu X, Xu F, Zhang L, Park JW, Hwang JY, Kong M, Liu Z, Zhang X, Xu R, Yan J, Merchant ML, McClain CJ, Zhang HG. Teng Y, et al. Nat Commun. 2025 Feb 3;16(1):1295. doi: 10.1038/s41467-025-56498-2. Nat Commun. 2025. PMID: 39900923 Free PMC article.
Colonization of germ-free male mice with gut bacteria from anti-PD-L1 non-responding patients supplemented with DHA enhances the efficacy of anti-PD-L1 therapy compared to controls. Our findings reveal a previously unknown mechanistic impact of PNP on human tumor immunothe …
Colonization of germ-free male mice with gut bacteria from anti-PD-L1 non-responding patients supplemented with DHA enhances the effi …
2,958 results